These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 8243232)

  • 1. [A study on the circadian variation of tissue-type plasminogen activator and its rapid inhibitor in patients with coronary heart disease].
    Chen ZY
    Zhonghua Xin Xue Guan Bing Za Zhi; 1993 Jun; 21(3):163-4, 188. PubMed ID: 8243232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circadian fluctuations of plasminogen activator inhibitor and tissue plasminogen activator levels in plasma of patients with unstable coronary artery disease and acute myocardial infarction.
    Huber K; Rosc D; Resch I; Schuster E; Glogar DH; Kaindl F; Binder BR
    Thromb Haemost; 1988 Dec; 60(3):372-6. PubMed ID: 3149044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Problems in measuring parameters of the fibrinolytic system: circadian rhythm of tissue-type plasminogen activator and plasminogen activator inhibitor].
    Köhler M; Miyashita C
    Klin Wochenschr; 1988; 66 Suppl 12():62-7. PubMed ID: 3126347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diurnal variation of tissue-type plasminogen activator and its rapid inhibitor (PAI-1).
    Angleton P; Chandler WL; Schmer G
    Circulation; 1989 Jan; 79(1):101-6. PubMed ID: 2491971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of tissue plasminogen activator and plasminogen activator inhibitor-I levels in acute myocardial infarction.
    Yamada S; Yamada R; Ishii A; Ashikawa K; Kawamitsu H; Fujita K
    J Cardiol; 1996 Apr; 27(4):171-8. PubMed ID: 8642503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of isotretinoin on endogenous tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor 1 (PAI-1) in humans.
    Wallnöfer AE; van Griensven JM; Schoemaker HC; Cohen AF; Lambert W; Kluft C; Meijer P; Kooistra T
    Thromb Haemost; 1993 Dec; 70(6):1005-8. PubMed ID: 8165591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relation of depressive mood to plasminogen activator inhibitor, tissue plasminogen activator, and fibrinogen levels in patients with versus without coronary heart disease.
    Lahlou-Laforet K; Alhenc-Gelas M; Pornin M; Bydlowski S; Seigneur E; Benetos A; Kierzin JM; Scarabin PY; Ducimetiere P; Aiach M; Guize L; Consoli SM
    Am J Cardiol; 2006 May; 97(9):1287-91. PubMed ID: 16635597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyperfibrinolysis in alcoholic cirrhosis: relative plasminogen activator inhibitor type 1 deficiency.
    Ferguson JW; Helmy A; Ludlam C; Webb DJ; Hayes PC; Newby DC
    Thromb Res; 2008; 121(5):675-80. PubMed ID: 17870147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transmyocardial fibrinolytic activity in patients with unstable angina pectoris.
    Daniel WC; Meidell RS; Hillis LD; Lange RA
    Coron Artery Dis; 1996 Jan; 7(1):45-9. PubMed ID: 8773432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Levels of tissue-type plasminogen activator (T-PA), its inhibitor (PAI-1) and fibrinogen in the blood of patients with type 1 and 2 diabetes mellitus].
    Kvasnicka J; Skrha J; Perusicová J; Maslowská H; Pochopová L
    Cas Lek Cesk; 1996 Mar; 135(6):174-7. PubMed ID: 8681360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Decreased fibrinolytic capacity in coronary patients by increased plasminogen activator inhibitor activity].
    Ihnken K; Speiser W; Müller-Berghaus G; Beyersdorf F; Schlepper M; Satter P
    Helv Chir Acta; 1992 Jan; 58(4):503-8. PubMed ID: 1582860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imbalance of plasminogen activator inhibitor type-1 (PAI-1) and tissue plasminogen activator (t-PA) activity in patients with Noonan syndrome.
    Mehta P; Parker RI
    J Pediatr Hematol Oncol; 2010 Oct; 32(7):532-6. PubMed ID: 20686427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Daytime fluctuations in blood of tissue-type plasminogen activator (t-PA) and its fast-acting inhibitor (PAI-1).
    Kluft C; Jie AF; Rijken DC; Verheijen JH
    Thromb Haemost; 1988 Apr; 59(2):329-32. PubMed ID: 3133814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tissue plasminogen activator (t-PA) and plasminogen activator inhibitor-I (PAI-I) levels in plasma and peritoneal effluent in patients on CAPD.
    Selgas R; Cuesta MV; Riñon C; Romero JR; de Alvaro F; Bajo MA; Sanchez-Sicilia L
    Adv Perit Dial; 1992; 8():160-5. PubMed ID: 1361777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasminogen activator inhibitor 1 is elevated in the children of men with premature myocardial infarction.
    Rallidis LS; Megalou AA; Papageorgakis NH; Trikas AG; Chatzidimitriou GI; Tsitouris GK
    Thromb Haemost; 1996 Sep; 76(3):417-21. PubMed ID: 8883280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma tissue plasminogen activator and plasminogen activator inhibitor-1 levels in acute myocardial infarction.
    Ganti AK; Potti A; Yegnanarayan R
    Pathophysiol Haemost Thromb; 2002; 32(2):80-4. PubMed ID: 12214153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sex differences in the determinants of fibrinolytic activity.
    MacCallum PK; Cooper JA; Howarth DJ; Meade TW; Miller GJ
    Thromb Haemost; 1998 Mar; 79(3):587-90. PubMed ID: 9531046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coagulation and fibrinolytic activity in patients with acute cerebral infarction.
    Li F; Zhang G; Zhao W
    Chin Med J (Engl); 2003 Mar; 116(3):475-7. PubMed ID: 12781064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship of plasminogen activator inhibitor-1 levels following thrombolytic therapy with rt-PA as compared to streptokinase and patency of infarct related coronary artery.
    Paganelli F; Alessi MC; Morange P; Maixent JM; Lévy S; Vague IJ
    Thromb Haemost; 1999 Jul; 82(1):104-8. PubMed ID: 10456462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasminogen activators (t-PA and u-PA) and plasminogen activators inhibitors (PAI-1 and PAI-2) in some myeloproliferative syndromes.
    Rość D; Kremplewska-Nalezyta E; Gadomska G; Zastawna E; Michalski A; Drewniak W
    Med Sci Monit; 2000; 6(4):684-91. PubMed ID: 11208392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.